Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Akari Therapeutics ( (AKTX) ) has provided an announcement.
Akari Therapeutics announced the appointment of Torsten Hombeck as the new Chief Financial Officer, effective December 16, 2024. Dr. Hombeck brings extensive experience in financial leadership within the healthcare and biopharmaceutical sectors, having served in similar roles at various companies including Aspira Women’s Health and Promethera Biosciences, which enhances Akari’s strategic positioning in the financial domain.
More about Akari Therapeutics
YTD Price Performance: -68.81%
Average Trading Volume: 40,065
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $11.82M
Learn more about AKTX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue